Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Penile Neoplasms | 33 | 2020 | 156 | 4.270 |
Why?
|
Carcinoma, Squamous Cell | 33 | 2020 | 4044 | 1.560 |
Why?
|
Carcinoma in Situ | 9 | 2020 | 779 | 0.870 |
Why?
|
Penis | 6 | 2011 | 209 | 0.730 |
Why?
|
Precancerous Conditions | 11 | 2020 | 976 | 0.550 |
Why?
|
Lichen Sclerosus et Atrophicus | 5 | 2020 | 26 | 0.530 |
Why?
|
Papillomavirus Infections | 9 | 2019 | 1640 | 0.450 |
Why?
|
Condylomata Acuminata | 5 | 2019 | 79 | 0.450 |
Why?
|
Anti-Inflammatory Agents | 2 | 2011 | 1808 | 0.360 |
Why?
|
Skin Neoplasms | 8 | 2018 | 5849 | 0.360 |
Why?
|
Micrococcaceae | 1 | 2010 | 8 | 0.350 |
Why?
|
Melanoma | 10 | 2018 | 5719 | 0.340 |
Why?
|
Papillomaviridae | 4 | 2019 | 1141 | 0.310 |
Why?
|
Adjuvants, Pharmaceutic | 1 | 2008 | 48 | 0.310 |
Why?
|
Trypanocidal Agents | 3 | 2015 | 40 | 0.310 |
Why?
|
Aluminum | 1 | 2008 | 150 | 0.300 |
Why?
|
Dermatitis | 1 | 2010 | 199 | 0.300 |
Why?
|
Pathology, Clinical | 2 | 2020 | 377 | 0.300 |
Why?
|
Nitroimidazoles | 3 | 2015 | 117 | 0.290 |
Why?
|
Trypanosoma cruzi | 4 | 2015 | 200 | 0.270 |
Why?
|
Alopecia | 1 | 2011 | 414 | 0.270 |
Why?
|
Granuloma | 1 | 2008 | 327 | 0.260 |
Why?
|
Antibodies, Monoclonal | 6 | 2014 | 9249 | 0.260 |
Why?
|
Cicatrix | 2 | 2010 | 798 | 0.250 |
Why?
|
Chagas Disease | 3 | 2013 | 163 | 0.250 |
Why?
|
Urethral Neoplasms | 1 | 2005 | 37 | 0.250 |
Why?
|
Tumor Virus Infections | 1 | 2007 | 440 | 0.230 |
Why?
|
Peripheral Nerves | 1 | 2008 | 491 | 0.230 |
Why?
|
Clinical Protocols | 1 | 2010 | 1441 | 0.230 |
Why?
|
Neprilysin | 1 | 2007 | 484 | 0.220 |
Why?
|
Phimosis | 1 | 2003 | 10 | 0.220 |
Why?
|
Urethra | 1 | 2005 | 406 | 0.210 |
Why?
|
Bacteremia | 1 | 2010 | 989 | 0.210 |
Why?
|
Adenocarcinoma, Clear Cell | 2 | 2016 | 218 | 0.200 |
Why?
|
Carcinoma, Basosquamous | 2 | 2012 | 7 | 0.200 |
Why?
|
Skin | 4 | 2010 | 4489 | 0.200 |
Why?
|
Papillomavirus Vaccines | 1 | 2008 | 496 | 0.200 |
Why?
|
Psoriasis | 1 | 2010 | 919 | 0.200 |
Why?
|
Endemic Diseases | 2 | 2012 | 189 | 0.180 |
Why?
|
Antigens, Neoplasm | 2 | 2011 | 2002 | 0.170 |
Why?
|
Balanitis Xerotica Obliterans | 1 | 2020 | 1 | 0.170 |
Why?
|
Lymphatic Metastasis | 6 | 2017 | 2887 | 0.170 |
Why?
|
Skin Diseases | 1 | 2008 | 1088 | 0.170 |
Why?
|
Urogenital Neoplasms | 1 | 2021 | 129 | 0.160 |
Why?
|
Lymph Nodes | 3 | 2010 | 3454 | 0.150 |
Why?
|
Neoplasm Invasiveness | 5 | 2010 | 3602 | 0.150 |
Why?
|
Chagas Cardiomyopathy | 2 | 2015 | 72 | 0.140 |
Why?
|
Biopsy | 4 | 2010 | 6763 | 0.140 |
Why?
|
Immunohistochemistry | 8 | 2020 | 11022 | 0.140 |
Why?
|
Carcinoma, Verrucous | 2 | 2010 | 27 | 0.130 |
Why?
|
Male | 47 | 2021 | 363691 | 0.130 |
Why?
|
Aged, 80 and over | 20 | 2020 | 59488 | 0.130 |
Why?
|
Nevus, Pigmented | 1 | 2018 | 227 | 0.130 |
Why?
|
Carcinoma, Papillary | 2 | 2012 | 788 | 0.130 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2010 | 9373 | 0.120 |
Why?
|
Paraguay | 3 | 2011 | 7 | 0.120 |
Why?
|
Penile Diseases | 1 | 2014 | 47 | 0.120 |
Why?
|
Neoplasm Staging | 4 | 2017 | 11206 | 0.110 |
Why?
|
Middle Aged | 33 | 2020 | 223004 | 0.110 |
Why?
|
Terminology as Topic | 2 | 2012 | 1534 | 0.110 |
Why?
|
Humans | 61 | 2021 | 765956 | 0.110 |
Why?
|
Neoplasm Metastasis | 3 | 2010 | 4893 | 0.110 |
Why?
|
Nifurtimox | 1 | 2013 | 14 | 0.110 |
Why?
|
Diagnosis, Differential | 7 | 2012 | 12976 | 0.100 |
Why?
|
Parakeratosis | 1 | 2012 | 2 | 0.100 |
Why?
|
Antibodies, Protozoan | 2 | 2013 | 250 | 0.100 |
Why?
|
Foreskin | 1 | 2011 | 33 | 0.100 |
Why?
|
Polymerase Chain Reaction | 6 | 2019 | 6069 | 0.100 |
Why?
|
Aged | 26 | 2020 | 171114 | 0.100 |
Why?
|
Nevus | 1 | 2013 | 205 | 0.090 |
Why?
|
Neoplasms, Basal Cell | 1 | 2011 | 30 | 0.090 |
Why?
|
Inhibitor of Apoptosis Proteins | 1 | 2011 | 202 | 0.090 |
Why?
|
Membrane Proteins | 1 | 2007 | 7851 | 0.090 |
Why?
|
Actinomycetales Infections | 1 | 2010 | 30 | 0.090 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2011 | 703 | 0.080 |
Why?
|
Merkel Cells | 1 | 2009 | 23 | 0.080 |
Why?
|
Behcet Syndrome | 1 | 2010 | 86 | 0.080 |
Why?
|
Acantholysis | 1 | 2009 | 11 | 0.080 |
Why?
|
Cysts | 1 | 2014 | 684 | 0.080 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2011 | 4348 | 0.080 |
Why?
|
Adult | 23 | 2020 | 223038 | 0.080 |
Why?
|
Pregnancy Complications, Parasitic | 1 | 2009 | 65 | 0.080 |
Why?
|
Melanocytes | 2 | 2009 | 515 | 0.080 |
Why?
|
Hyperplasia | 3 | 2011 | 1144 | 0.080 |
Why?
|
Gene Expression Profiling | 3 | 2018 | 9524 | 0.080 |
Why?
|
Prognosis | 8 | 2012 | 29921 | 0.070 |
Why?
|
SOXB1 Transcription Factors | 1 | 2009 | 282 | 0.070 |
Why?
|
Crohn Disease | 2 | 2011 | 2283 | 0.070 |
Why?
|
Point Mutation | 1 | 2013 | 1590 | 0.070 |
Why?
|
Melanoma, Amelanotic | 1 | 2007 | 19 | 0.070 |
Why?
|
In Situ Hybridization | 2 | 2016 | 1886 | 0.070 |
Why?
|
Keratinocytes | 1 | 2012 | 863 | 0.070 |
Why?
|
Cytoplasm | 1 | 2012 | 1500 | 0.070 |
Why?
|
Pathology, Molecular | 2 | 2021 | 330 | 0.070 |
Why?
|
Opportunistic Infections | 1 | 2010 | 376 | 0.070 |
Why?
|
Plasma Cells | 1 | 2010 | 591 | 0.070 |
Why?
|
Drug Therapy | 1 | 2010 | 504 | 0.070 |
Why?
|
Lipodystrophy | 1 | 2007 | 145 | 0.070 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 3807 | 0.060 |
Why?
|
Head and Neck Neoplasms | 2 | 2010 | 2921 | 0.060 |
Why?
|
Eosinophils | 1 | 2010 | 945 | 0.060 |
Why?
|
Autopsy | 1 | 2009 | 1011 | 0.060 |
Why?
|
Circumcision, Male | 2 | 2004 | 148 | 0.060 |
Why?
|
Young Adult | 9 | 2020 | 59886 | 0.060 |
Why?
|
Keratosis | 1 | 2005 | 80 | 0.060 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 1761 | 0.060 |
Why?
|
Genes, Neoplasm | 1 | 2007 | 370 | 0.060 |
Why?
|
Immunocompromised Host | 1 | 2010 | 866 | 0.060 |
Why?
|
Scalp | 1 | 2007 | 388 | 0.060 |
Why?
|
Survival Analysis | 2 | 2007 | 10070 | 0.060 |
Why?
|
Metaplasia | 1 | 2005 | 326 | 0.060 |
Why?
|
Immunologic Memory | 1 | 2011 | 1375 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2008 | 723 | 0.060 |
Why?
|
Endpoint Determination | 1 | 2007 | 591 | 0.060 |
Why?
|
Genotype | 5 | 2019 | 13024 | 0.050 |
Why?
|
Societies, Medical | 2 | 2020 | 3956 | 0.050 |
Why?
|
Epithelium | 2 | 2005 | 1599 | 0.050 |
Why?
|
Reproducibility of Results | 3 | 2018 | 20125 | 0.050 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2007 | 587 | 0.050 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2005 | 416 | 0.050 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2007 | 488 | 0.050 |
Why?
|
Antigens, CD | 2 | 2011 | 4025 | 0.050 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2011 | 2899 | 0.050 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2011 | 4642 | 0.040 |
Why?
|
Consensus | 1 | 2010 | 3202 | 0.040 |
Why?
|
Argentina | 2 | 2012 | 249 | 0.040 |
Why?
|
Practice Guidelines as Topic | 1 | 2017 | 7425 | 0.040 |
Why?
|
Female | 18 | 2015 | 396101 | 0.040 |
Why?
|
Down-Regulation | 1 | 2007 | 2927 | 0.040 |
Why?
|
Neoplasm Proteins | 1 | 2011 | 3596 | 0.040 |
Why?
|
Risk Factors | 3 | 2017 | 74836 | 0.040 |
Why?
|
Rectal Neoplasms | 1 | 2008 | 1182 | 0.040 |
Why?
|
World Health Organization | 2 | 2018 | 1328 | 0.040 |
Why?
|
Valine | 1 | 2000 | 410 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 1410 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2021 | 11083 | 0.040 |
Why?
|
Piperazines | 1 | 2008 | 2549 | 0.040 |
Why?
|
Skin Aging | 1 | 1998 | 140 | 0.030 |
Why?
|
Adolescent | 8 | 2020 | 88832 | 0.030 |
Why?
|
United States | 2 | 2017 | 72898 | 0.030 |
Why?
|
Pyrimidines | 1 | 2008 | 3047 | 0.030 |
Why?
|
Human papillomavirus 18 | 1 | 2016 | 125 | 0.030 |
Why?
|
Urology | 1 | 2020 | 384 | 0.030 |
Why?
|
Predictive Value of Tests | 2 | 2010 | 15398 | 0.030 |
Why?
|
Tumor Suppressor Proteins | 1 | 2005 | 2796 | 0.030 |
Why?
|
Arthritis, Rheumatoid | 1 | 2010 | 3733 | 0.030 |
Why?
|
Epitopes | 2 | 2011 | 2523 | 0.030 |
Why?
|
Recurrence | 1 | 2007 | 8501 | 0.030 |
Why?
|
Tetrazoles | 1 | 2000 | 920 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2009 | 8611 | 0.030 |
Why?
|
Human papillomavirus 16 | 1 | 2016 | 268 | 0.030 |
Why?
|
T-Lymphocytes, Cytotoxic | 2 | 2011 | 1801 | 0.030 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2001 | 790 | 0.030 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2010 | 3645 | 0.030 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2000 | 1061 | 0.030 |
Why?
|
Insulin | 1 | 2007 | 6599 | 0.030 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 11868 | 0.030 |
Why?
|
Antibodies, Neoplasm | 1 | 2014 | 282 | 0.030 |
Why?
|
Comorbidity | 1 | 2007 | 10563 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2009 | 8927 | 0.030 |
Why?
|
GTP-Binding Protein alpha Subunits | 1 | 2013 | 103 | 0.020 |
Why?
|
GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2013 | 149 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2018 | 2505 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2007 | 12769 | 0.020 |
Why?
|
Face | 1 | 1998 | 1028 | 0.020 |
Why?
|
MART-1 Antigen | 1 | 2011 | 65 | 0.020 |
Why?
|
DNA, Protozoan | 1 | 2012 | 226 | 0.020 |
Why?
|
HLA-A2 Antigen | 1 | 2011 | 207 | 0.020 |
Why?
|
Antihypertensive Agents | 1 | 2000 | 2033 | 0.020 |
Why?
|
Drug Administration Schedule | 2 | 2014 | 4850 | 0.020 |
Why?
|
Laser Therapy | 1 | 1998 | 1108 | 0.020 |
Why?
|
Antigens, Protozoan | 1 | 2013 | 314 | 0.020 |
Why?
|
Interleukin-15 | 1 | 2011 | 186 | 0.020 |
Why?
|
France | 1 | 2011 | 495 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2007 | 17075 | 0.020 |
Why?
|
Sensitivity and Specificity | 2 | 2018 | 14652 | 0.020 |
Why?
|
Treatment Outcome | 6 | 2014 | 65189 | 0.020 |
Why?
|
Chronic Disease | 2 | 2015 | 9347 | 0.020 |
Why?
|
Treatment Failure | 1 | 2015 | 2652 | 0.020 |
Why?
|
Ki-67 Antigen | 1 | 2011 | 629 | 0.020 |
Why?
|
Adoptive Transfer | 1 | 2011 | 827 | 0.020 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2014 | 1106 | 0.020 |
Why?
|
Chymases | 1 | 2007 | 85 | 0.020 |
Why?
|
Neoplasm Seeding | 1 | 2008 | 85 | 0.020 |
Why?
|
Cromolyn Sodium | 1 | 2007 | 76 | 0.020 |
Why?
|
Antigen-Presenting Cells | 1 | 2011 | 962 | 0.020 |
Why?
|
Disease-Free Survival | 2 | 2010 | 6832 | 0.020 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2008 | 104 | 0.020 |
Why?
|
Immunity, Humoral | 1 | 2011 | 605 | 0.020 |
Why?
|
Genetic Testing | 1 | 2020 | 3595 | 0.020 |
Why?
|
Brain Neoplasms | 1 | 2008 | 9071 | 0.020 |
Why?
|
Tryptases | 1 | 2007 | 177 | 0.020 |
Why?
|
Stem Cell Niche | 1 | 2009 | 346 | 0.020 |
Why?
|
Arm | 1 | 2009 | 589 | 0.020 |
Why?
|
Nasal Mucosa | 1 | 2009 | 416 | 0.020 |
Why?
|
Keratins | 1 | 2007 | 498 | 0.020 |
Why?
|
Nose | 1 | 2009 | 519 | 0.020 |
Why?
|
Specimen Handling | 1 | 2010 | 704 | 0.020 |
Why?
|
Carcinoma, Merkel Cell | 1 | 2009 | 328 | 0.020 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2007 | 266 | 0.020 |
Why?
|
Proportional Hazards Models | 2 | 2015 | 12509 | 0.020 |
Why?
|
Antineoplastic Agents | 1 | 2008 | 13648 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2013 | 4108 | 0.010 |
Why?
|
Mice, SCID | 1 | 2009 | 2630 | 0.010 |
Why?
|
Anastomosis, Surgical | 1 | 2008 | 990 | 0.010 |
Why?
|
Interleukin-2 | 1 | 2011 | 1896 | 0.010 |
Why?
|
Phylogeny | 1 | 2012 | 2832 | 0.010 |
Why?
|
Child, Preschool | 3 | 2013 | 42500 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 2014 | 2631 | 0.010 |
Why?
|
Embryonic Stem Cells | 1 | 2009 | 1241 | 0.010 |
Why?
|
Benzamides | 1 | 2008 | 1377 | 0.010 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2009 | 1354 | 0.010 |
Why?
|
Immune Tolerance | 1 | 2011 | 2324 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2014 | 10729 | 0.010 |
Why?
|
Cell Differentiation | 2 | 2010 | 11640 | 0.010 |
Why?
|
Central Nervous System | 1 | 2008 | 1341 | 0.010 |
Why?
|
Mucous Membrane | 1 | 2004 | 657 | 0.010 |
Why?
|
Up-Regulation | 1 | 2010 | 4137 | 0.010 |
Why?
|
Mutation | 2 | 2020 | 30196 | 0.010 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2011 | 2942 | 0.010 |
Why?
|
Phenotype | 2 | 2011 | 16721 | 0.010 |
Why?
|
Mast Cells | 1 | 2007 | 1412 | 0.010 |
Why?
|
Research Design | 2 | 2010 | 6208 | 0.010 |
Why?
|
Time Factors | 2 | 2013 | 40065 | 0.010 |
Why?
|
Captopril | 1 | 2000 | 261 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 2000 | 11501 | 0.010 |
Why?
|
PTEN Phosphohydrolase | 1 | 2005 | 1119 | 0.010 |
Why?
|
Cell Movement | 1 | 2011 | 5194 | 0.010 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2011 | 4405 | 0.010 |
Why?
|
Radiosurgery | 1 | 2008 | 1328 | 0.010 |
Why?
|
Heart | 1 | 2012 | 4414 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2018 | 16047 | 0.010 |
Why?
|
Child | 3 | 2013 | 80563 | 0.010 |
Why?
|
Disease Progression | 1 | 2015 | 13631 | 0.010 |
Why?
|
Angiotensin II | 1 | 2000 | 844 | 0.010 |
Why?
|
Radiography | 1 | 2008 | 6919 | 0.010 |
Why?
|
Sample Size | 1 | 2000 | 845 | 0.010 |
Why?
|
Diagnostic Errors | 1 | 2004 | 1275 | 0.010 |
Why?
|
Rhytidoplasty | 1 | 1998 | 72 | 0.010 |
Why?
|
Genetic Variation | 1 | 2012 | 6610 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2008 | 8529 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2017 | 26313 | 0.010 |
Why?
|
Apoptosis | 1 | 2011 | 9514 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2008 | 4209 | 0.010 |
Why?
|
Multicenter Studies as Topic | 1 | 2000 | 1731 | 0.010 |
Why?
|
Epithelial Cells | 1 | 2007 | 3681 | 0.010 |
Why?
|
Survival Rate | 1 | 2009 | 12795 | 0.010 |
Why?
|
Hypoglycemic Agents | 1 | 2007 | 3110 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2013 | 22222 | 0.010 |
Why?
|
Prospective Studies | 2 | 2015 | 54806 | 0.010 |
Why?
|
Prevalence | 1 | 2011 | 15839 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2009 | 18973 | 0.010 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2000 | 1514 | 0.010 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2007 | 3446 | 0.010 |
Why?
|
Carcinoma | 1 | 2004 | 2312 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2000 | 6309 | 0.010 |
Why?
|
Transcription Factors | 1 | 2009 | 12131 | 0.010 |
Why?
|
Cause of Death | 1 | 2000 | 3708 | 0.010 |
Why?
|
Cohort Studies | 1 | 2013 | 41647 | 0.010 |
Why?
|
Adenocarcinoma | 1 | 2007 | 6364 | 0.010 |
Why?
|
Algorithms | 1 | 2010 | 14071 | 0.010 |
Why?
|
Infant | 1 | 2012 | 36385 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2015 | 15651 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2005 | 10429 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2009 | 26349 | 0.000 |
Why?
|
Patient Selection | 1 | 2000 | 4255 | 0.000 |
Why?
|
Odds Ratio | 1 | 2000 | 9649 | 0.000 |
Why?
|
Follow-Up Studies | 1 | 2009 | 39194 | 0.000 |
Why?
|
Pregnancy | 1 | 2009 | 30258 | 0.000 |
Why?
|
Double-Blind Method | 1 | 2000 | 12437 | 0.000 |
Why?
|
Retrospective Studies | 1 | 2013 | 81515 | 0.000 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2000 | 10383 | 0.000 |
Why?
|
Mice | 1 | 2009 | 81818 | 0.000 |
Why?
|
Animals | 1 | 2009 | 168759 | 0.000 |
Why?
|
Postoperative Complications | 1 | 1998 | 15747 | 0.000 |
Why?
|